# Case Report: Unveiling the role of genetic abnormalities in myelomatous pleural effusion: a case of IgG lambda-type multiple myeloma

## TL;DR

A 73-year-old man with multiple myeloma showed improvement after treatment for myelomatous pleural effusion using a combination of chemotherapy and supportive care.

## Contribution

This case report highlights the effectiveness of personalized treatment for myelomatous pleural effusion in multiple myeloma.

## Key findings

- The patient's pleural effusion resolved after PDD chemotherapy and supportive therapies.
- No myeloma cells were detected in the pleural fluid post-treatment.
- Personalized treatment approaches improved clinical outcomes in this complex case.

## Abstract

A 73-year-old male with a history of multiple myeloma presented with progressively worsening left shoulder pain that was unresponsive to conservative management. Following comprehensive diagnostic procedures, including imaging and genetic testing, he was diagnosed with IgG lambda-type multiple myeloma, complicated by the development of myelomatous pleural effusion (MPE). The patient’s treatment regimen consisted of the PDD chemotherapy combination, including Bortezomib, Doxorubicin, and Dexamethasone, alongside adjunctive therapies aimed at controlling the pleural effusion. Post-treatment evaluation revealed resolution of the pleural effusion, with no detectable myeloma cells in the pleural fluid. This case illustrates the clinical utility of combining chemotherapy with supportive treatments for the effective management of MPE in multiple myeloma patients. The patient’s positive response highlights the significance of tailoring therapeutic approaches to the individual, emphasizing the role of personalized care in improving clinical outcomes in similar complex cases of MPE.